|
RITONAVIR SHOULD NOT BE CO-ADMINISTERED WITH CISAPRIDE,ASTEMIZOLE,MIDAZOLAM,TRIAZOLAM OR ERGOT DERIVATIVES BECAUSE COMPITITION FOR CYP3A4 BY EFAVIRENZ MAY RESULT IN INHIBITION OF OTHER DRUGS METABOLISM LEADING TO SERIOUS SIDE EFFECTS LIKE ARRHYTHMIAS
|
AVOID CONCOMITANT PRESCRIPTION WITH MEDICATIONS KNOWN TO PROLONG QTC INTERVAL LIKE ERYTHROMYCIN, TERFENADINE, ASTEMIZOLE, CISAPRIDE, PENTAMIDINE, TRICYCLIC ANTIDEPRESSANTS & SOME ANTIPSYCHOTICS INCLUDING PHENOTHIAZINES
|
AVOID CONCOMITANT PRESCRIPTION WITH MEDICATIONS KNOWN TO PROLONG QTC INTERVAL LIKE ERYTHROMYCIN, TERFENADINE, ASTEMIZOLE, CISAPRIDE, PENTAMIDINE, TRICYCLIC ANTIDEPRESSANTS & SOME ANTIPSYCHOTICS INCLUDING PHENOTHIAZINES
|
AVOID CONCOMITANT PRESCRIPTION WITH MEDICATIONS KNOWN TO PROLONG QTC INTERVAL LIKE ERYTHROMYCIN, TERFENADINE, ASTEMIZOLE, CISAPRIDE, PENTAMIDINE, TRICYCLIC ANTIDEPRESSANTS & SOME ANTIPSYCHOTICS INCLUDING PHENOTHIAZINES
|
AVOID CONCOMITANT PRESCRIPTION WITH MEDICATIONS KNOWN TO PROLONG QTC INTERVAL LIKE ERYTHROMYCIN, TERFENADINE, ASTEMIZOLE, CISAPRIDE, PENTAMIDINE, TRICYCLIC ANTIDEPRESSANTS & SOME ANTIPSYCHOTICS INCLUDING PHENOTHIAZINES
|
AVOID CONCOMITANT PRESCRIPTION WITH MEDICATIONS KNOWN TO PROLONG QTC INTERVAL LIKE ERYTHROMYCIN, TERFENADINE, ASTEMIZOLE, CISAPRIDE, PENTAMIDINE, TRICYCLIC ANTIDEPRESSANTS & SOME ANTIPSYCHOTICS INCLUDING PHENOTHIAZINES
|
AVOID CONCOMITANT PRESCRIPTION WITH MEDICATIONS KNOWN TO PROLONG QTC INTERVAL LIKE ERYTHROMYCIN, TERFENADINE, ASTEMIZOLE, CISAPRIDE, PENTAMIDINE, TRICYCLIC ANTIDEPRESSANTS & SOME ANTIPSYCHOTICS INCLUDING PHENOTHIAZINES
|
AVOID CONCOMITANT PRESCRIPTION WITH MEDICATIONS KNOWN TO PROLONG QTC INTERVAL LIKE ERYTHROMYCIN, TERFENADINE, ASTEMIZOLE, CISAPRIDE, PENTAMIDINE, TRICYCLIC ANTIDEPRESSANTS & SOME ANTIPSYCHOTICS INCLUDING PHENOTHIAZINES
|
AVOID CONCOMITANT PRESCRIPTION WITH MEDICATIONS KNOWN TO PROLONG QTC INTERVAL LIKE ERYTHROMYCIN, TERFENADINE, ASTEMIZOLE, CISAPRIDE, PENTAMIDINE, TRICYCLIC ANTIDEPRESSANTS & SOME ANTIPSYCHOTICS INCLUDING PHENOTHIAZINES
|
AVOID CONCOMITANT PRESCRIPTION WITH MEDICATIONS KNOWN TO PROLONG QTC INTERVAL LIKE ERYTHROMYCIN, TERFENADINE, ASTEMIZOLE, CISAPRIDE, PENTAMIDINE, TRICYCLIC ANTIDEPRESSANTS & SOME ANTIPSYCHOTICS INCLUDING PHENOTHIAZINES
|
AVOID CONCOMITANT PRESCRIPTION WITH MEDICATIONS KNOWN TO PROLONG QTC INTERVAL LIKE ERYTHROMYCIN, TERFENADINE, ASTEMIZOLE, CISAPRIDE, PENTAMIDINE, TRICYCLIC ANTIDEPRESSANTS & SOME ANTIPSYCHOTICS INCLUDING PHENOTHIAZINES
|
CONTRAINDICATED DUE TO POTENTIAL FOR SERIOUS &/OR LIFE THREATENING REACTIONS LIKE CARDIAC ARRHYTHMIAS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
INDINAVIR SHOULD NOT BE CO-ADMINISTERED WITH CISAPRIDE,ASTEMIZOLE,MIDAZOLAM,TRIAZOLAM OR ERGOT DERIVATIVES BECAUSE COMPITITION FOR CYP3A4 BY EFAVIRENZ MAY RESULT IN INHIBITION OF OTHER DRUGS METABOLISM LEADING TO SERIOUS SIDE EFFECTS LIKE ARRHYTHMIAS
|
INDINAVIR SHOULD NOT BE CO-ADMINISTERED WITH CISAPRIDE,ASTEMIZOLE,MIDAZOLAM,TRIAZOLAM OR ERGOT DERIVATIVES BECAUSE COMPITITION FOR CYP3A4 BY EFAVIRENZ MAY RESULT IN INHIBITION OF OTHER DRUGS METABOLISM LEADING TO SERIOUS SIDE EFFECTS LIKE ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION MAY CAUSE PROLONGATION OF Q-T INTERVAL LEADING TO INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION MAY CAUSE PROLONGATION OF Q-T INTERVAL LEADING TO INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
CISAPRIDE ENHANCES THE GASTRIC ABSORPTION OF THE DRUG
|
CISAPRIDE ENHANCES THE GASTRIC ABSORPTION OF THE DRUG
|
PROLONGATION OF QT INTERVAL MAY BE SERIOUS COMPLICATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|
CONCURRENT ADMINISTRATION OF ANTICHOLENERGIC COMPOUNDS WOULD BE EXPECTED TO COMPROMISE THE BENEFICIAL EFFECTS OF CISAPRIDE
|